

# Bicarbonate for Chronic Kidney Disease and Acidosis

|                                        |                                                              |                                                                                                              |
|----------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| <b>Submission date</b><br>14/02/2012   | <b>Recruitment status</b><br>No longer recruiting            | <input checked="" type="checkbox"/> Prospectively registered<br><input checked="" type="checkbox"/> Protocol |
| <b>Registration date</b><br>17/02/2012 | <b>Overall study status</b><br>Completed                     | <input type="checkbox"/> Statistical analysis plan<br><input checked="" type="checkbox"/> Results            |
| <b>Last Edited</b><br>18/03/2021       | <b>Condition category</b><br>Urological and Genital Diseases | <input type="checkbox"/> Individual participant data                                                         |

## Plain English summary of protocol

### Background and study aims

Many people with chronic kidney disease have higher than usual levels of acid in the blood. Higher levels of acid may worsen kidney function, blood vessel health and bone health, as well as stopping your muscles from working as well as they should. This in turn may make people feel tired and reduce quality of life. Acid levels can be treated with sodium bicarbonate (used in baking powder); this is used as a treatment in some people with kidney disease and high levels of acid. We do not know whether the benefits of this treatment (on muscle, bone, kidneys, blood vessels and quality of life) are greater than the potential side effects (such as raising blood pressure, fluid retention and having to take extra tablets).

We therefore aim to test whether taking daily bicarbonate tablets improves physical function, quality of life, bone and blood vessel health in patients with advanced chronic kidney disease and high levels of acid in the blood.

### Who can participate?

People aged 60 and over who have advanced chronic kidney disease, but who are not on dialysis

### What does the study involve?

The study takes 2 years in total to complete. The study is of randomised, double-blind design. This means that you will be asked to take medication by mouth three times a day. This will either contain bicarbonate, or a placebo (dummy) medication. The one that you will be given is decided in a random way (a bit like tossing a coin, but done by a computer). Neither you nor the research team will know which you are taking until after the study is finished. This means that the results of the study cannot be influenced by you or the researchers knowing what you are taking.

Participants will receive either sodium bicarbonate or placebo (dummy tablets), starting with 1 tablet three times a day, rising to two tablets three times a day after 3 months. We will do the following tests at each study visit, which take place before the start of the study then at 3, 6, 12 and 24 months. We will measure your blood pressure while you are sitting down. We will check your height and weight. We will take a blood test (about two tablespoons of blood). Blood samples will be stored and tested at the end of the study. We will ask you to bring a urine sample with you. You will be asked to do some mobility tests: - standing tests, balance tests, timed getting up from a chair and a test to measure your hand grip strength. You will be asked to walk up and down a corridor for six minutes at your own pace. We will measure how far you

can walk in that time. We will ask you two questionnaires about your quality of life and how your kidney problems affect your quality of life.

What are the possible benefits and risks of participating?

Taking part in the trial will allow us to see if bicarbonate treatment improves the health and physical function of people with acidosis and chronic kidney disease. This dose of sodium bicarbonate is commonly used in people with kidney disease. Increase in blood pressure, fluid retention and bloating are experienced by some people, and we will be asking you about these side effects at each visit. Having blood taken can cause some bruising. The blood pressure cuff causes mild discomfort to some people.

Where is the study run from?

The study is run from the University of Dundee and centres in Aberdeen, Canterbury, Dundee, Salford, Sheffield, Preston, Portsmouth, Mid Essex, Manchester, Leicester, North Midlands, Pennine, Wolverhampton, Highland, Wirral, Sussex, Exeter, Plymouth, Southend, Fife, Gloucestershire and Birmingham (UK).

When is the study starting and how long is it expected to run for?

The study will start recruitment in July 2012. Results are anticipated to be available in June 2018; participants will be recruited for the first 18 months of the trial.

Who is funding the study?

The Health Technology Assessment board (HTA) of the National Institute for Health Research, UK

Who is the main contact?

Dr Miles D Witham  
m.witham@dundee.ac.uk

## Contact information

### Type(s)

Scientific

### Contact name

Prof Miles Witham

### ORCID ID

<https://orcid.org/0000-0002-1967-0990>

### Contact details

NIHR Newcastle Biomedical Research Centre  
Newcastle University  
Campus for Ageing and Vitality  
Newcastle  
United Kingdom  
NE4 5PL

-  
Miles.Witham@newcastle.ac.uk

### Type(s)

Scientific

**Contact name**

Ms Margaret Band

**Contact details**

BiCARB Trial Manager  
Tayside Clinical Trials Unit  
Residency Block  
Level 3  
Ninewells Hospital & Medical School  
Dundee  
United Kingdom  
DD1 9SY  
+44 (0)1382 383 993  
m.band@dundee.ac.uk

**Additional identifiers**

**Clinical Trials Information System (CTIS)**

2011-005271-16

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

2010NE02; HTA 10/71/01

**Study information**

**Scientific Title**

Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis?

**Acronym**

BiCARB

**Study objectives**

To determine whether oral bicarbonate therapy improves physical function and quality of life compared to placebo in older people with Chronic Kidney disease and mild acidosis.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

East of Scotland Research Ethics Service REC 2, 16/03/2012

**Study design**

Randomised double-blind parallel-group placebo-controlled trial

## Primary study design

Interventional

## Study type(s)

Quality of life

## Health condition(s) or problem(s) studied

Chronic kidney disease

## Interventions

Oral sodium bicarbonate 500 mg three times a day, rising to 1 g three times a day or matching placebo

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Sodium bicarbonate

## Primary outcome(s)

Change in Short Physical Performance Battery (SPPB) between baseline and 12 months

## Key secondary outcome(s)

Current secondary outcome measures as of 10/07/2015:

1. EQ-5D
2. SPPB (baseline, 3, 6, 24 months)
3. Serum sodium, potassium, magnesium, urea, bicarbonate, calcium, phosphate, alkaline phosphatase, creatinine (eGFR calculated by MDRD4 equation), albumin, haemoglobin, thyroid function, HbA1c, lipids
4. Cystatin C
5. Urinary protein/creatinine ratio and urinary albumin/creatinine ratio
6. Height (at screening visit only), weight and anthropometric data (mid arm circumference; triceps skinfold thickness; mid thigh circumference)
7. Handgrip strength measured using dynamometry
8. Six minute walk test
9. KDQoL, a disease-specific quality of life measure
10. Office blood pressure. 3 readings will be taken; the mean of the 2nd and 3rd reading will be used as the outcome
11. Commencement on dialysis
12. All-cause mortality (via General Register Office death records)
13. Death from end-stage renal failure
14. Cardiovascular mortality
15. All hospitalisations (via hospital and GP morbidity records; including heart failure, other cardiovascular and renal-related hospitalisations)
16. Outpatients and general practitioner (GP) visits
17. Changes in medication use, with particular focus on vascular medications and phosphate binders
18. Fractures will be recorded by direct patient report, verified with GP and hospital records

- 19. Falls will be recorded prospectively using the validated falls diary method
  - 20. Information on side effects (e.g. nausea, indigestion, ankle oedema) will be sought by patient self-report. Adherence to study medication will be assessed by tablet counting.
  - 21. Bone and Vascular Secondary outcomes (measured at baseline, 12 and 24 months)
    - 21.1. Serum markers of bone turnover: bone-specific alkaline phosphatase and tartrate-resistant acid-phosphatase 5b
    - 21.2. Parathyroid hormone (PTH), 25-hydroxy vitamin D (25OHD) and 1,25OHD
    - 21.3. B-type natriuretic peptide
- Measured at baseline, 3, 6, 12, and 24 months

Previous secondary outcome measures:

- 1. EQ-5D
  - 2. SPPB (baseline, 3, 6, 24 months)
  - 3. Serum sodium, potassium, magnesium, urea, bicarbonate, calcium, phosphate, alkaline phosphatase, creatinine (eGFR calculated by MDRD4 equation), albumin, haemoglobin, thyroid function, HbA1c, lipids
  - 4. Cystatin C
  - 5. Urinary protein/creatinine ratio and urinary albumin/creatinine ratio
  - 6. Height (at screening visit only), weight and anthropometric data (mid arm circumference; triceps skinfold thickness; mid thigh circumference)
  - 7. Handgrip strength measured using dynamometry
  - 8. Six minute walk test
  - 9. KDQoL, a disease-specific quality of life measure
  - 10. Office Blood pressure. 3 readings will be taken; the mean of the 2nd and 3rd reading will be used as the outcome
  - 11. Commencement on dialysis
  - 12. All-cause mortality (via General Register Office death records)
  - 13. Death from end-stage renal failure
  - 14. Cardiovascular mortality
  - 15. All hospitalisations (via hospital and GP morbidity records; including heart failure, other cardiovascular and renal-related hospitalisations)
  - 16. Outpatients and general practitioner (GP) visits
  - 17. Changes in medication use, with particular focus on vascular medications and phosphate binders
  - 18. Fractures will be recorded by direct patient report, verified with GP and hospital records
  - 19. Falls will be recorded prospectively using the validated falls diary method
  - 20. Information on side effects (e.g. nausea, indigestion, ankle oedema) will be sought by patient self-report. Adherence to study medication will be assessed by tablet counting.
  - 21. Bone and Vascular substudy - Secondary outcomes (measured at baseline, 12 and 24 months) on up to 150 patients
    - 21.1. Bone mineral density at femoral neck and forearm using DEXA.
    - 21.2. Body composition using DEXA.
    - 21.3. Serum markers of bone turnover: bone-specific alkaline phosphatase and tartrate-resistant acid-phosphatase 5b
    - 21.4. Parathyroid hormone (PTH), 25-hydroxy vitamin D (25OHD) and 1,25OHD
    - 21.5. Arterial stiffness, measured using pulse wave velocity and augmentation index
    - 21.6. B-type natriuretic peptide
- Measured at baseline, 3, 6, 12, and 24 months

**Completion date**

30/09/2018

# Eligibility

## Key inclusion criteria

Current inclusion criteria as of 10/07/2015:

1. Participant is willing and able to give informed consent for participation in the study
2. Male or female aged 60 years or above
3. Estimated Glomerular Filtration Rate (eGFR) <30 ml/min (i.e. CKD stages 4 and 5) found at screening visit
4. Serum Bicarbonate <22 mmol/L
5. Able (in the Investigators opinion) and willing to comply with all study requirements

Previous inclusion criteria:

1. Participant is willing and able to give informed consent for participation in the study
2. Male or female aged 65 years or above
3. Estimated Glomerular Filtration Rate (eGFR) <30 ml/min (i.e. CKD stages 4 and 5) found at screening visit
4. Serum Bicarbonate <22 mmol/L
5. Able (in the Investigators opinion) and willing to comply with all study requirements

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Senior

## Sex

All

## Total final enrolment

300

## Key exclusion criteria

Current exclusion criteria as of 10/07/2015:

1. Severe cognitive impairment precluding written informed consent
2. Already taking bicarbonate therapy; those taking bicarbonate therapy may be included after a 3 month washout period.
3. Documented renal tubular acidosis (such patients are likely to require bicarbonate, often in very large doses)
4. On renal replacement therapy (haemodialysis or peritoneal dialysis)
5. Anticipated to start renal replacement therapy within 3 months
6. Severe cognitive impairment precluding written informed consent
7. Participant who is terminally ill, as defined as less than 3 months expected survival
8. Decompensated chronic heart failure (to ensure that fluid overload is not exacerbated by the additional sodium load from the intervention)
9. Bisphosphonate therapy (to avoid obscuring bone turnover effects; patients with CKD stages 4 /5 should not usually be taking bisphosphonates as this is a listed contraindication)
10. Uncontrolled hypertension (BP>150/90 despite use of four agents) unless evidence of well controlled blood pressure e.g. 24 hour BP readings or home readings

Previous exclusion criteria:

1. Severe cognitive impairment precluding written informed consent
2. Already taking bicarbonate therapy
3. Documented renal tubular acidosis (such patients are likely to require bicarbonate, often in very large doses)
4. On renal replacement therapy (haemodialysis or peritoneal dialysis)
5. Anticipated to start renal replacement therapy within 3 months
6. Severe cognitive impairment precluding written informed consent
7. Participant who is terminally ill, as defined as less than 3 months expected survival
8. Decompensated chronic heart failure (to ensure that fluid overload is not exacerbated by the additional sodium load from the intervention)
9. Bisphosphonate therapy (to avoid obscuring bone turnover effects; patients with CKD stages 4 /5 should not usually be taking bisphosphonates as this is a listed contraindication)
10. Calcium carbonate use (to avoid interaction with bicarbonate)
11. Sevelamer hydrochloride use (to avoid increasing acid load)
12. Uncontrolled hypertension (BP>150/90 despite use of four agents)

**Date of first enrolment**

01/07/2012

**Date of final enrolment**

31/03/2016

## Locations

**Countries of recruitment**

United Kingdom

Scotland

**Study participating centre**

**Ninewells Hospital**

Dundee

United Kingdom

DD1 9SY

## Sponsor information

**Organisation**

Tayside Medical Sciences Centre (UK)

**ROR**

<https://ror.org/000ywep40>

# Funder(s)

## Funder type

Government

## Funder Name

Health Technology Assessment Programme

## Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

De-identified participant level data will be available from the Chief Investigator or the Sponsor to bona-fide academic research teams, subject to submission of a proposal for data use, analysis and publication, and approval by a data-sharing committee.

Previous publication and dissemination plan criteria:

Planned publication in high-impact peer reviewed journal, estimated mid to late 2019.

## IPD sharing statement

De-identified participant level data will be available from the Chief Investigator or the Sponsor to bona-fide academic research teams, subject to submission of a proposal for data use, analysis and publication, and approval by a data-sharing committee.

## IPD sharing plan summary

Available on request

## Study outputs

| Output type                      | Details  | Date created | Date added | Peer reviewed? | Patient-facing? |
|----------------------------------|----------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a>  | results  | 01/12/2020   | 09/04/2020 | Yes            | No              |
| <a href="#">Protocol article</a> | protocol | 01/08/2015   |            | Yes            | No              |
| <a href="#">Basic results</a>    |          | 22/02/2019   | 22/02/2019 | No             | No              |

|                                    |                                                                                                |  |                |                |     |     |
|------------------------------------|------------------------------------------------------------------------------------------------|--|----------------|----------------|-----|-----|
| <a href="#">Basic results</a>      |                                                                                                |  | 21/04<br>/2020 | No             | No  |     |
| <a href="#">Other publications</a> | HTA report                                                                                     |  | 01/06<br>/2020 | 23/06<br>/2020 | Yes | No  |
| <a href="#">Other publications</a> | secondary analysis of associations between frailty, physical performance, and renal biomarkers |  | 01/03<br>/2021 | 18/03<br>/2021 | Yes | No  |
| <a href="#">Study website</a>      | Study website                                                                                  |  | 11/11<br>/2025 | 11/11<br>/2025 | No  | Yes |